| anti-CTLA-4 | atezolizumab based treatment | nivolumab based treatment | anti-PD-(L)1 | Immune checkpoint association |
| tremelimumab | atezolizumab plus cometinib | atezolizumab plus SoC | nivolumab alone | nivolumab followed by ipilimumab | nivolumab plus ipilimumab | relatlimab plus nivolumab |
mML - 1st line (L1) | | | | | | | |
mML - L1 - all population 7 | | | | | | | |
mML - L1 - BRAF mutant 2 | | | | | | | |
mML - L1 - BRAF wild 3 | | | | | | | |